Publication:
Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.

dc.contributor.authorGimeno, Juan R
dc.contributor.authorOlivotto, Iacopo
dc.contributor.authorRodríguez, Ana Isabel
dc.contributor.authorHo, Carolyn Y
dc.contributor.authorFernández, Adrián
dc.contributor.authorQuiroga, Alejandro
dc.contributor.authorEspinosa, Mari Angeles
dc.contributor.authorGómez-González, Cristina
dc.contributor.authorRobledo, María
dc.contributor.authorTojal-Sierra, Lucas
dc.contributor.authorDay, Sharlene M
dc.contributor.authorOwens, Anjali
dc.contributor.authorBarriales-Villa, Roberto
dc.contributor.authorLarrañaga, Jose María
dc.contributor.authorRodríguez-Palomares, Jose
dc.contributor.authorGonzález-Del-Hoyo, Maribel
dc.contributor.authorPiqueras-Flores, Jesús
dc.contributor.authorReza, Nosheen
dc.contributor.authorChumakova, Olga
dc.contributor.authorAshley, Euan A
dc.contributor.authorParikh, Victoria
dc.contributor.authorWheeler, Matthew
dc.contributor.authorJacoby, Daniel
dc.contributor.authorPereira, Alexandre C
dc.contributor.authorSaberi, Sara
dc.contributor.authorHelms, Adam S
dc.contributor.authorVillacorta, Eduardo
dc.contributor.authorGallego-Delgado, María
dc.contributor.authorde Castro, Daniel
dc.contributor.authorDomínguez, Fernando
dc.contributor.authorRipoll-Vera, Tomás
dc.contributor.authorZorio-Grima, Esther
dc.contributor.authorSánchez-Martínez, José Carlos
dc.contributor.authorGarcía-Álvarez, Ana
dc.contributor.authorArbelo, Elena
dc.contributor.authorMogollón, María Victoria
dc.contributor.authorFuentes-Cañamero, María Eugenia
dc.contributor.authorGrande, Elias
dc.contributor.authorPeña, Carlos
dc.contributor.authorMonserrat, Lorenzo
dc.contributor.authorLakdawala, Neal K
dc.date.accessioned2023-12-20T13:37:54Z
dc.date.available2023-12-20T13:37:54Z
dc.date.issued2022-08
dc.description.abstractAIMS To describe the natural history of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. METHODS AND RESULTS Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS-Cov-2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS-CoV-2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty-nine (22.9%) HCM patients were hospitalized for non-ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS-CoV-2-related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12-4.51], P = 0.0229}, baseline New York Heart Association class [OR per one-unit increase 4.01 (95%CI: 1.75-9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16-26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20-49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community-based SARS-CoV-2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98-2.91, P = 0.0600). CONCLUSIONS Over one-fourth of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.es_ES
dc.description.peerreviewedes_ES
dc.format.number4es_ES
dc.format.page2189es_ES
dc.format.volume9es_ES
dc.identifier.citationESC Heart Fail. 2022 Aug;9(4):2189-2198.es_ES
dc.identifier.doi10.1002/ehf2.13964es_ES
dc.identifier.e-issn2055-5822es_ES
dc.identifier.journalESC heart failurees_ES
dc.identifier.pubmedID36255281es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/16855
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.relation.publisherversion10.1002/ehf2.13964es_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución-CompartirIgual 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-sa/4.0/*
dc.subject.meshCOVID-19es_ES
dc.subject.meshCardiomyopathy, Hypertrophices_ES
dc.subject.meshVentricular Dysfunction, Leftes_ES
dc.subject.meshAtrial Fibrillationes_ES
dc.subject.meshHumanses_ES
dc.subject.meshMalees_ES
dc.subject.meshAdultes_ES
dc.subject.meshMiddle Agedes_ES
dc.subject.meshAgedes_ES
dc.subject.meshFemalees_ES
dc.subject.meshSARS-CoV-2es_ES
dc.subject.meshRegistrieses_ES
dc.titleImpact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Impact of SARS_Cov_2_ESC Heart Fail_2022.pdf
Size:
1.53 MB
Format:
Adobe Portable Document Format
Description:
Artículo